Release date: 2015-03-26
Pear Therapeutics, a Boston-based medical startup, has recently received investments from venture capital firms such as 5AM Ventures. The exact amount is unknown.
Pear Therapeutics has developed a product called "eFormulations" that combines drugs for specific diseases with digital therapies. To use eFormulations, patients need to be prescribed by a doctor.
Depending on the patient's illness, the software portion of the eFormulations product may include games, tracking tools, or other forms of interaction.
Pear Therapeutics CEO Corey McCann said: "Unlike other products, we are praising the intervention, which will enhance the treatment. For the treatment of depression, if I am a depression patient I will also receive antidepressants and cognitive behavioral therapy (CBT). Of course, the CBT here has been digitized, and in some cases, the digital version of CBT is more effective than the CBT in the office."
“We can create a multi-modal treatment, such as antidepressants plus CBT software. This example shows how we can integrate two things together while stimulating the brain and then achieving better results than using the drug alone. â€
During this process, eFormulations collects patient data and sends it to the doctor. Each treatment plan collects different data sets depending on the patient's disease. But usually, eFormulations collects patient input data, user performance data in games or other activities, and some passive monitoring data, such as voice data and accelerometer data, which requires patient consent. Passive monitoring data is primarily used to assess a patient's mood.
According to McCann, the Pear Therapeutics program is the first to introduce eFormulations solutions for addiction, post-traumatic stress disorder (PTSD), depression, generalized anxiety disorder and sleep disorders. After that, the company will launch another five products, but it has not yet been approved by the US Food and Drug Administration (FDA). Pear Therapeutics plans to apply for a 510(k) license for its software, and then apply for a 505(b)(2) license for products that integrate software and drugs.
McCann said: "By integrating drugs and software, we have created a combination of drugs and devices. Just as with inhalers and dry powders, asthma is the device, dry powder is the drug. But in our solution, The device becomes software, drugs or drugs."
Source: Singularity Network
We specialize in developing and producing stretchers,anti-coronavirus products, first-aid product, Funeral Products, ward products, Diagnosis Device, emergency rescue product and so on. We supply one stop purchasing of Medical Equipment for all overseas customers.
Emergency Bed,Stainless Steel Emergency Bed,Emergency Patient Bed,Medical Emergency Bed
Medton Medical , https://www.medtonmedical.com